Skip to main content
. 2016 Aug 9;7(36):58051–58064. doi: 10.18632/oncotarget.11160

Figure 6. Sensitivity of UKF-NB-3 and its sub-line with acquired resistance to SNS-032 (UKF-NB-3rSNS-032300nM) to CDK inhibition by alternative inhibitors or by siRNA-mediated CDK depletion.

Figure 6

(A) Relative sensitivity of UKF-NB-3 and UKF-NB-3rSNS-032300nM to the CDK2, 7, and 9 inhibitor seliciclib, the CDK7 inhibitor LDC000067, the CDK9 inhibitor BS-181, or the CDK 1,2,4,6,7, and 9 inhibitor alvocidib. Numerical values are presented in Supplementary Table S1F. (B) Effects of siRNA-mediated depletion of CDK7, CDK9, or CDK7 and CDK9 on UKF-NB-3 and UKF-NB-3rSNS-032300nM cell viability as determined by MTT assay 72 h post-transfection. Non-targeting ‘scrambled’ siRNA (scr siRNA) served as control. Western blots indicating siRNA-mediated effects on protein levels are presented in Supplementary Figure S6. Numerical values are presented in Supplementary Table S1G. * P < 0.05 relative to scr siRNA.